Dariusz Sawka

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Tyrosine kinase inhibitors – should we worry about cardiovascular complications?

K. Styczkiewicz, D. Sawka, M. Styczkiewicz, 2017 .

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma

J. Larkin, M. Hurwitz, M. Sznol, 2019 .

Renal complications in multiple myeloma – principles of treatment

A. Pluta, B. Kumiega, Dariusz Sawka, 2010 .